Abstract:CBF beta was recently found to be a key regulator of the ability of human immunodeficiency virus type 1 (HIV-1) Vif to overcome host antiviral APOBEC3 proteins. However, the detailed molecular requirements for the Vif-CBF beta interaction are still not clear. Here, we mapped the minimum Vif domain required for CBF beta binding. In terms of CBF beta binding, the Vif N terminus was very sensitive to deletions. We determined that the Vif fragment from residues 5 to 126 was sufficient to form a stable complex with CBF beta in vitro. We also observed that ionic interactions were not the main contributor to the interaction between Vif and CBF beta. Instead, hydrophobic interactions were important for maintaining the Vif-CBF beta complex, since it could be disrupted by nonionic detergent. Site-directed mutagenesis of conserved hydrophobic amino acids revealed novel residues in Vif that were important for CBF beta binding and APOBEC3 inactivation. At least part of the well-characterized HCCH domain (residues 108 to 139) was required to form a stable Vif-CBF beta complex. Thus, the HCCH motif may have a dual role in binding both Cul5 and CBF beta. Considering the importance of Vif in HIV-1 infection, this unique Vif-CBF beta interaction represents an attractive pharmacological intervention target against HIV-1. IMPORTANCE Vif-induced APOBEC3 protein degradation was the first host antiviral mechanism against HIV-1/simian immunodeficiency virus to be revealed, yet details regarding which proteins are degraded are not fully demonstrated. Recently, host cellular factor CBF beta was found to be essential for Vif to function and promote viral infectivity. In this study, we present more critical information on the Vif-CBF beta interaction by revealing that hydrophobicity contributes the most to the Vif-CBF beta interaction and locating several novel hydrophobic sites (tryptophans and phenylalanines) that are conserved among Vif proteins from different lentiviruses and essential for Vif binding to CBF beta. Mutations on these sites result in a reduced/abolished Vif-CBF beta interaction, leading to the attenuated potency of Vif on both inducing the degradation of antiviral factors like APOBEC3G and promoting HIV-1 infectivity. Therefore, information from this study will help people to further understand how Vif acts against host antiviral mechanism, which is important for novel anti-HIV-1 drug development.

Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction

Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction

[Progress in the Study of HIV-1 Vif and Related Inhibitors].

Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression.

Identification of HIV-1 Vif regions required for CBF-β interaction and APOBEC3 suppression.

Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Three-dimensional Structure of HIV-1 VIF Constructed by Comparative Modeling and the Function Characterization Analyzed by Molecular Dynamics Simulation

Conserved interaction of lentiviral Vif molecules with HIV-1 Gag and differential effects of species-specific Vif on virus production.

A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction

A Naturally Occurring Vif Mutant (I107T) Attenuates Anti-Apobec3g Activity and HIV-1 Replication.

Design, synthesis, and biological evaluation of 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif inhibitors.

Structural Basis of Antagonism of Human APOBEC3F by HIV-1 Vif

The structure and function of HIV-1 accessory protein Vif

Characterization of the Interaction of Full-Length HIV-1 Vif Protein with Its Key Regulator CBFβ and CRL5 E3 Ubiquitin Ligase Components

Abilities of HIV-1 founder virus Vpu and Vif to counteract host restriction factor

Association of Human Immunodeficiency Virus Type 1 Vif with RNA and Its Role in Reverse Transcription.

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to Sifuvirtide, a Novel HIV-1 Fusion Inhibitor

Multiple lysines combined in HIV-1 Vif determines the responsiveness to CBF-β.

Various strategies for developing APOBEC3G protectors to circumvent human immunodeficiency virus type 1

Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F

Identification of an Hiv-1 Replication Inhibitor Which Rescues Host Restriction Factor Apobec3g in Vif-Apobec3g Complex